Analysts’ Viewpoint on Non-invasive Cancer Diagnostics Market Scenario
Cancer awareness and early detection have increased over the last few decades, resulting in a decrease in mortality rates. Early diagnosis requires ensuring rapid patient presentation, diagnosis, and treatment. Advancements in sensors, contrast agents, molecular methods, and Artificial Intelligence (AI) that assist in detecting cancer-specific signals in real time is expected to drive the global non-invasive cancer diagnostics market during the forecast period. Risk-based detection and prevention needs to be cost-effective and widely accessible in order to reduce the burden of cancer on the society. Maximizing detection accuracy with a cost-effective approach facilitated by non-invasive cancer diagnostic techniques is likely to propel the global market in the next few years. Companies in the market are investing significantly in the research & development of improved non-invasive cancer diagnostics.
Cancer is a disease, in which some of the body's cells grow uncontrollably and spread to other parts. It is a group of more than 100 different diseases, which develop almost anywhere in the body. Diagnostic testing of cancer involves tests and procedures to confirm the presence of the disease, and identification of the correct tumor type, location, extent, and stage. Cancer diagnosis is performed with various methods or techniques such as physical exam, laboratory tests, imaging tests, and biopsy. Oncologists use one or more approaches to diagnose cancer. These techniques are categorized into invasive or minimally invasive and non-invasive. Invasive cancer diagnosis (painstaking cancer diagnosis) or minimally invasive cancer diagnosis techniques include laboratory test (blood test) and biopsy, while non-invasive cancer diagnosis (unintrusive cancer diagnosis) techniques comprise imaging tests, physical exam, spectroscopy, and laboratory test (urine test).
Increase in geriatric population, surge in incidence of cancer, rise in technological advancements in imaging equipment, and shift in preference toward non-invasive cancer diagnosis techniques are the major factors propelling the global market. According to the World Health Organization (WHO), the global population aged 60 years or above stood at 1 billion in 2020 and is anticipated to reach 1.4 billion by 2030 and 2.1 billion by 2050. Thus, the population of people aged 60 years and older will double by 2050 compared to that in 2020. Furthermore, the number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million by 2050. This geriatric population is more prone to chronic diseases such as cancer. This is projected to boost the demand for cancer diagnosis. In turn, this is anticipated to augment the global non-invasive cancer diagnostics market size from 2022 to 2031. According to statistics published by the Global Cancer Observatory, the number of new cancer cases across the world stood at 19,292,789 in 2020.
COVID-19 had a negative effect on the non-invasive cancer diagnostics market in 2020. The unprecedented outbreak of the COVID-19 pandemic largely affected countries in North America and Europe such as the U.S., Italy, Spain, the U.K., France, and Germany. Implementation of lockdowns due to COVID-19 outbreak delayed the diagnosis of cancer. It also affected the logistics and supply of cancer diagnosis equipment or products. Nationwide lockdowns, government regulations, and increase in infection rate across countries created a widespread financial impact on cancer hospitals and outpatient centers. Several hospitals and clinics witnessed a drop in number of patient visits amid COVID-19, ultimately reducing client contact. Furthermore, several cancer diagnostic procedures and non-invasive cancer treatments were delayed due to the pandemic. Limited availability of healthcare staff was another factor that restrained the cancer diagnostics market.
In terms of test type, the imaging test segment held the largest global non-invasive cancer diagnostics market share in 2021. The trend is expected to continue during the forecast period due to the increase in patient preference for imaging tests. Ultrasound, Magnetic Resonance Imaging (MRI), Computerized Tomography (CT), mammography, Positron Emission Tomography (PET), X-ray/mammography, and liquid biopsy are non-invasive diagnostic tests for cancer detection. These tests are simpler and less expensive than blood or plasma tests. Hence, increasing number of cancer patients are opting for painless imaging tests to diagnose and monitor cancer progression.
The urine test segment is likely to dominate the global non-invasive cancer diagnostics market during the forecast period owing to the rise in adoption of the urinalysis test to check for traces of blood, bacteria, or abnormal cells in the urine in cancer or bladder cancer diagnosis cases.
Based on cancer type, the breast cancer segment held substantial share of the global market in 2021. This can be ascribed to the surge in incidence of breast cancer across the globe and increase in population of women aged 50 to 74. Rise in initiatives by various organizations for early screening and diagnosis of breast cancer is projected to augment the segment in the next few years. According to the Global Cancer Observatory, 2,261,419 breast cancer cases were reported across the world in 2020.
Lung cancer is projected to be a lucrative segment of the global market during the forecast period, as it is the leading cancer in the U.S. and across the globe. According to the Centers for Disease Control and Prevention (CDC), cigarette smoking is linked to about 80% to 90% of lung cancer deaths in the U.S. Rise in usage of chest X-ray, CT, MRI, PET, and bone scans for lung cancer diagnosis is likely to propel the lung cancer segment from 2022 to 2031.
In terms of end-user, the hospitals & clinics segment held the largest share of the global market in 2021. This can be ascribed to the increase in number of hospitals and rise in non-invasive cancer diagnostic procedures in this setting. According to the American Hospital Association (AHA), the number of hospitals in the U.S. rose from 5,564 in 2017 to 6,093 in 2022. Increase in number of hospitals in the region has led to a surge in number of cancer diagnosis tests performed.
According to the global non-invasive cancer diagnostics market analysis, North America accounted for significant share of the market in 2021. This can be ascribed to changing demographics, evolving lifestyle, increase in incidence of cancer, and presence of well-established point-of-care diagnostic centers in the U.S. and Canada. For instance, the number of new cancer cases in North America stood at 2,556,862 in 2020.
The market in Asia Pacific is expected to grow at a rapid pace during the forecast period. Increase in geriatric population, surge in incidence of cancer, and rise in awareness about non-invasive equipment for cancer diagnosis are expected to augment the market in the region during the forecast period. Governments of Japan, China, and India fund and support universities and research institutes in order to develop new technologies for cancer diagnosis. This is driving the market for non-invasive cancer diagnostics in the region.
The non-invasive cancer diagnostics market report concludes with the company profiles section that includes key information about the major players in the global non-invasive cancer diagnostics market. Market participants are focusing on strategies such as new product or solution offerings, mergers, and partnerships & collaborations to compete in the global market. The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Beverly Hills Cancer Center, SimonMed Imaging, RadNet Management, Inc., RAYUS Radiology (Diagnostic Services Holdings, Inc.), Unilabs AB, Sonic Healthcare Limited, and Dr Lal PathLabs Ltd. are the prominent players operating in the global market.
Each of these players has been profiled in the non-invasive cancer diagnostics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 104.8 Bn |
|
Market Forecast Value in 2031 |
More than US$ 207 Bn |
|
Compound Annual Growth Rate (CAGR) |
7.0% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global non-invasive cancer diagnostics market was valued at US$ 104.8 Bn in 2021
The global non-invasive cancer diagnostics market is projected to reach more than US$ 207 Bn by 2031
The global non-invasive cancer diagnostics market is anticipated to grow at a CAGR of 7.0% from 2022 to 2031
Increase in geriatric population, rise in incidence of cancer, surge in technological advancements in imaging equipment, and shift in preference toward non-invasive cancer diagnosis techniques
The imaging test segment accounted for more than 59% share of the global non-invasive cancer diagnostics market in 2021
North America is expected to account for major share of the global non-invasive cancer diagnostics market during the forecast period
The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Beverly Hills Cancer Center, SimonMed Imaging, RadNet Management, Inc., RAYUS Radiology (Diagnostic Services Holdings, Inc.), Unilabs AB, Sonic Healthcare Limited, and Dr Lal PathLabs Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Non-invasive Cancer Diagnostics Market
4. Market Overview
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Non-invasive Cancer Diagnostics Market Value Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Technological Advancements
5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Test Type, 2017–2031
6.3.1. Urine Test
6.3.2. Imaging Test
6.3.2.1. Computerized Tomography
6.3.2.2. Magnetic Resonance Imaging
6.3.2.3. Nuclear Medicine Scans
6.3.2.4. X-ray/Mammography
6.3.2.5. Ultrasound
6.3.3. Spectroscopy
6.4. Market Attractiveness Analysis, by Test Type
7. Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Cancer Type, 2017–2031
7.3.1. Breast Cancer
7.3.2. Lung Cancer
7.3.3. Blood Cancer
7.3.4. Ovarian Cancer
7.3.5. Colorectal Cancer
7.3.6. Others
7.4. Market Attractiveness Analysis, by Cancer Type
8. Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals & Clinics
8.3.2. Ambulatory Care
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Non-invasive Cancer Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Test Type, 2017–2031
10.2.1. Urine Test
10.2.2. Imaging Test
10.2.2.1. Computerized Tomography
10.2.2.2. Magnetic Resonance Imaging
10.2.2.3. Nuclear Medicine Scans
10.2.2.4. X-ray/Mammography
10.2.2.5. Ultrasound
10.2.3. Spectroscopy
10.3. Market Value Forecast, by Cancer Type, 2017–2031
10.3.1. Breast Cancer
10.3.2. Lung Cancer
10.3.3. Blood Cancer
10.3.4. Ovarian Cancer
10.3.5. Colorectal Cancer
10.3.6. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals & Clinics
10.4.2. Ambulatory Care
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Test Type
10.6.2. By Cancer Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Non-invasive Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Test Type, 2017–2031
11.2.1. Urine Test
11.2.2. Imaging Test
11.2.2.1. Computerized Tomography
11.2.2.2. Magnetic Resonance Imaging
11.2.2.3. Nuclear Medicine Scans
11.2.2.4. X-ray/Mammography
11.2.2.5. Ultrasound
11.2.3. Spectroscopy
11.3. Market Value Forecast, by Cancer Type, 2017–2031
11.3.1. Breast Cancer
11.3.2. Lung Cancer
11.3.3. Blood Cancer
11.3.4. Ovarian Cancer
11.3.5. Colorectal Cancer
11.3.6. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals & Clinics
11.4.2. Ambulatory Care
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Test Type
11.6.2. By Cancer Type
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Non-invasive Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Test Type, 2017–2031
12.2.1. Urine Test
12.2.2. Imaging Test
12.2.2.1. Computerized Tomography
12.2.2.2. Magnetic Resonance Imaging
12.2.2.3. Nuclear Medicine Scans
12.2.2.4. X-ray/Mammography
12.2.2.5. Ultrasound
12.2.3. Spectroscopy
12.3. Market Value Forecast, by Cancer Type, 2017–2031
12.3.1. Breast Cancer
12.3.2. Lung Cancer
12.3.3. Blood Cancer
12.3.4. Ovarian Cancer
12.3.5. Colorectal Cancer
12.3.6. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals & Clinics
12.4.2. Ambulatory Care
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Test Type
12.6.2. By Cancer Type
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Non-invasive Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Test Type, 2017–2031
13.2.1. Urine Test
13.2.2. Imaging Test
13.2.2.1. Computerized Tomography
13.2.2.2. Magnetic Resonance Imaging
13.2.2.3. Nuclear Medicine Scans
13.2.2.4. X-ray/Mammography
13.2.2.5. Ultrasound
13.2.3. Spectroscopy
13.3. Market Value Forecast, by Cancer Type, 2017–2031
13.3.1. Breast Cancer
13.3.2. Lung Cancer
13.3.3. Blood Cancer
13.3.4. Ovarian Cancer
13.3.5. Colorectal Cancer
13.3.6. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals & Clinics
13.4.2. Ambulatory Care
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Test Type
13.6.2. By Cancer Type
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Non-invasive Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Test Type, 2017–2031
14.2.1. Urine Test
14.2.2. Imaging Test
14.2.2.1. Computerized Tomography
14.2.2.2. Magnetic Resonance Imaging
14.2.2.3. Nuclear Medicine Scans
14.2.2.4. X-ray/Mammography
14.2.2.5. Ultrasound
14.2.3. Spectroscopy
14.3. Market Value Forecast, by Cancer Type, 2017–2031
14.3.1. Breast Cancer
14.3.2. Lung Cancer
14.3.3. Blood Cancer
14.3.4. Ovarian Cancer
14.3.5. Colorectal Cancer
14.3.6. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals & Clinics
14.4.2. Ambulatory Care
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Test Type
14.6.2. By Cancer Type
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Company Profiles
15.2.1. The University of Texas MD Anderson Cancer Center
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Company Financials
15.2.1.3. Growth Strategies
15.2.1.4. SWOT Analysis
15.2.2. Memorial Sloan Kettering Cancer Center
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Company Financials
15.2.2.3. Growth Strategies
15.2.2.4. SWOT Analysis
15.2.3. Dana-Farber Cancer Institute
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Company Financials
15.2.3.3. Growth Strategies
15.2.3.4. SWOT Analysis
15.2.4. Beverly Hills Cancer Center
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Company Financials
15.2.4.3. Growth Strategies
15.2.4.4. SWOT Analysis
15.2.5. SimonMed Imaging
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Company Financials
15.2.5.3. Growth Strategies
15.2.5.4. SWOT Analysis
15.2.6. RadNet Management, Inc.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Company Financials
15.2.6.3. Growth Strategies
15.2.6.4. SWOT Analysis
15.2.7. RAYUS Radiology (Diagnostic Services Holdings, Inc.)
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Company Financials
15.2.7.3. Growth Strategies
15.2.7.4. SWOT Analysis
15.2.8. Unilabs AB
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Company Financials
15.2.8.3. Growth Strategies
15.2.8.4. SWOT Analysis
15.2.9. Sonic Healthcare Limited
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Company Financials
15.2.9.3. Growth Strategies
15.2.9.4. SWOT Analysis
15.2.10. Dr Lal PathLabs Ltd.
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Company Financials
15.2.10.3. Growth Strategies
15.2.10.4. SWOT Analysis
List of Tables
Table 01: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 02: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 03: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 06: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 07: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 08: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 09: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 10: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 11: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 14: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 15: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 16: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 18: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 19: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 20: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 21: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 22: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 23: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 24: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031
Figure 03: Global Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031
Figure 04: Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type 2021 and 2031
Figure 05: Global Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031
Figure 06: Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031
Figure 07: Global Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 08: Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Region, 2021 and 2031
Figure 09: Global Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Region, 2022–2031
Figure 10: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 11: North America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031
Figure 12: North America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031
Figure 13: North America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type, 2021 and 2031
Figure 14: North America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031
Figure 15: North America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031
Figure 16: North America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 17: North America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Country, 2021 and 2031
Figure 18: North America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Country, 2022–2031
Figure 19: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 20: Europe Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031
Figure 21: Europe Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031
Figure 22: Europe Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type. 2021 and 2031
Figure 23: Europe Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031
Figure 24: Europe Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031
Figure 25: Europe Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 26: Europe Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 27: Europe Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 28: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 29: Asia Pacific Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031
Figure 30: Asia Pacific Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031
Figure 31: Asia Pacific Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type 2021 and 2031
Figure 32: Asia Pacific Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031
Figure 33: Asia Pacific Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031
Figure 34: Asia Pacific Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 35: Asia Pacific Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 36: Asia Pacific Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 37: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 38: Latin America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031
Figure 39: Latin America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031
Figure 40: Latin America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type, 2021 and 2031
Figure 41: Latin America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031
Figure 42: Latin America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031
Figure 43: Latin America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 44: Latin America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 45: Latin America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 46: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 47: Middle East & Africa Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031
Figure 48: Middle East & Africa Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031
Figure 49: Middle East & Africa Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type, 2021 and 2031
Figure 50: Middle East & Africa Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031
Figure 51: Middle East & Africa Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031
Figure 52: Middle East & Africa Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031
Figure 53: Middle East & Africa Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 54: Middle East & Africa Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 55: Global Non-invasive Cancer Diagnostics Market Share Analysis/Ranking, by Company, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Non-Invasive Cancer Diagnostics Market
